Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

Last updated: February 3, 2025
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma

Hematologic Cancer

Follicular Lymphoma

Treatment

blood sampling

Clinical Study ID

NCT06813573
2023-A02716-39
2023-3670
  • Ages > 18
  • All Genders

Study Summary

The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically proven diagnosis of diffuse large B cell lymphoma or follicularlymphoma, according to the WHO 2016 classification, requiring a first line oftreatment with a RCHOP 21 regimen

  • Agreement to participate after receiving oral and written information on the study

Exclusion

Exclusion Criteria:

  • History of previous treatment for lymphoma (excluding localized low doseradiotherapy in the case of follicular lymphoma)

  • Treatment with a chemotherapy regimen different from RCHOP21

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: blood sampling
Phase:
Study Start date:
September 30, 2024
Estimated Completion Date:
October 31, 2029

Connect with a study center

  • Gustave Roussy

    Villejuif, 94800
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.